UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

Core Viewpoint - UNITY Biotechnology, Inc. reported its financial results for Q1 2025, highlighting ongoing clinical trials and financial performance, including a net loss and cash position [1][4][5]. Financial Performance - As of March 31, 2025, cash, cash equivalents, and marketable securities totaled $16.9 million, down from $23.2 million as of December 31, 2024, with expectations to fund operations into Q4 2025 [4]. - The net loss for Q1 2025 was $7.3 million, compared to a net loss of $5.8 million in Q1 2024, with cash used in operations increasing to $6.4 million from $5.2 million year-over-year [5]. - Research and development expenses decreased by $0.9 million to $2.9 million, primarily due to reduced direct research costs and personnel expenses [6]. - General and administrative expenses increased by $0.2 million to $4.0 million, driven by higher professional fees and operating costs, partially offset by reduced personnel-related expenses [7]. Clinical Development - UNITY announced topline data from the Phase 2b ASPIRE study for diabetic macular edema (DME), showing vision improvements with UBX1325 comparable to aflibercept, although the primary endpoint was not met at weeks 20 and 24 [2][3]. - The full 36-week data is anticipated in Q2 2025, which will inform future study plans [3]. Company Overview - UNITY is focused on developing therapeutics aimed at slowing, halting, or reversing diseases of aging, particularly targeting age-related ophthalmologic and neurologic diseases [8].